|The rPSB rpsb (Catalog #MBS5300642) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The rPSB antibody (FITC) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s rPSB can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Immunohistochemistry (IHC), Western Blot (WB). Researchers should empirically determine the suitability of the rPSB rpsb for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The rPSB rpsb product has the following accession number(s) (GI #154351917) (NCBI Accession #ABS73996.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Rabbit polyclonal rPSB antibody (FITC).
Biological Significance: Some nascent polypeptide chains are able to cross-link to rPSB in situ. Tag/Conjugate: FITC
Immunogen: rPSB antibody (FITC) was raised in Rabbit using recombinant human 30S ribosomal protein S2 protein as the immunogen. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing rPSB are readily searchable from our website. Different antibodies against the same target such as rPSB may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.